GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been...
GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine
YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease...